Skip to content

Enovis ENOV Purchase of royalty interest

Purchase of royalty interest at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$0-100%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$0
Energy Fuels logo
Energy FuelsUUUU
$9.06M+112%
Xencor logo
XencorXNCR
$0
XOMA Corporation logo
XOMA CorporationXOMA
-$5.04M
Perrigo Company logo
Perrigo CompanyPRGO
$1.4M-17.6%

Other financials

Income statement

See full
Revenue$589.2M+5.4%
Gross profit$365.5M+10.0%
Operating income$6.5M+114%
Net income-$8.8M+84.3%
EPS (diluted)-$0.15+84.7%

Balance sheet

See full
Cash & equivalents$33.1M-13.9%
Total debt$1.4B-3.1%
Total equity$1.5B-43.6%
Total assets$3.8B-21.4%

Cash flow

See full
Operating cash flow$24.0M+1,601%
CapEx$52.8M+22.1%
Free cash flow-$28.9M+35.7%

Valuation

See full
Market cap$1.23B-28.4%
Enterprise value$2.55B-17.1%
P/S0.5×-0.3×

Profitability

See full
Gross margin60.5%+4.0pp
Operating margin-47%+18.6pp
Net margin-49.9%+24.1pp
FCF margin-3.1%-1.1pp

Returns & leverage

See full
Return on equity-55.5%-1,722pp
Debt / equity0.9×+0.4×
Current ratio-0.5×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept cfx:PurchaseOfRoyaltyInterest.

The official record: Enovis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enovis's purchase of royalty interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Enovis's purchase of royalty interest?
Enovis (ENOV) reported purchase of royalty interest of $0 in Q1 2026.
How has Enovis's purchase of royalty interest changed year-over-year?
Enovis's purchase of royalty interest decreased by 100.0% year-over-year, from $35.78M to $0.
What does purchase of royalty interest mean?
This metric represents cash outflows related to the acquisition of rights to future revenue streams or intellectual property royalties from third parties. It reflects a strategic capital allocation choice to secure long-term income or technology access rather than relying solely on internal R&D. Investors monitor this to assess how the company supplements its product pipeline and manages long-term intangible asset obligations.